Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

536.12 +3.30 (+0.62%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

February 25, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

February 24, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

February 19, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?

February 14, 2025

United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.

Via StockStory

Topics Stocks

How Is The Market Feeling About United Therapeutics? ↗

January 01, 2025

Via Benzinga

$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today ↗

December 11, 2024

Via Benzinga

How Is The Market Feeling About United Therapeutics? ↗

November 26, 2024

Via Benzinga

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

February 04, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

February 03, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

January 21, 2025

From United Therapeutics Corporation

Via Business Wire

Earnings Outlook For United Therapeutics ↗

October 29, 2024

Via Benzinga

Decoding 7 Analyst Evaluations For United Therapeutics ↗

October 21, 2024

Via Benzinga

The Analyst Landscape: 7 Takes On United Therapeutics ↗

October 21, 2024

Via Benzinga

$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

October 15, 2024

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Announces Successful World’s First UKidney Transplant

December 17, 2024

From United Therapeutics Corporation

Via Business Wire

Peering Into United Therapeutics's Recent Short Interest ↗

October 10, 2024

Via Benzinga

A Look Into United Therapeutics Inc's Price Over Earnings ↗

October 03, 2024

Via Benzinga

Key Takeaways From United Therapeutics Analyst Ratings ↗

September 23, 2024

Via Benzinga

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

November 05, 2024

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

October 30, 2024

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

October 23, 2024

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

October 23, 2024

From United Therapeutics Corporation

Via Business Wire

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗

October 15, 2024

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Via Investor's Business Daily

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗

October 14, 2024

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Via Investor's Business Daily

U.S. Stock: United Therapeutics Corp ↗

September 25, 2024

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.

Via Talk Markets

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗

September 24, 2024

Via Benzinga

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

September 24, 2024

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

September 10, 2024

From United Therapeutics Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.